The noninvasive follicular variant of papillary thyroid carcinoma (PTC) has an indolent clinical behavior in comparison with other PTCs, including the invasive follicular variant of papillary thyroid carcinoma (IFVPTC). Recently, the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced to emphasize the low biological potential of these tumors. This study compares clinical, cytological, and molecular features of NIFTP and IFVPTC. METHODS: The study consisted of 97 thyroid fine-needle aspiration biopsy (FNAB) cases with corresponding surgical pathology from the pathology archives of the Massachusetts General Hospital. The collected patient data included the following: age, sex, type of surgery, tumor size, and prior cytological diagnosis with The Bethesda System for Reporting Thyroid Cytopathology. A molecular analysis using anchored multiplex polymerase chain reaction was performed for all cases. Each case was reviewed and subclassified histologically as NIFTP or IFVPTC. Cytology slides were scored semiquantitatively for nuclear atypia. The statistical analysis was performed with the nonparametric Mann-Whitney test. RESULTS: The 97-case cohort consisted of 50 NIFTP cases and 47 IFVPTC cases, including 18 encapsulated IFVPTC cases and 29 nonencapsulated IFVPTC cases. Differences in the type of surgery (P 5.0399), molecular features (P 5.0141), cytological classification (P 5.0266), and nuclear scores (P 5.0141) between NIFTP and IFVPTC were observed.
INTRODUCTION
Follicular variant of papillary thyroid carcinoma (FVPTC) is a tumor with a follicular growth pattern and with nuclear features such as enlargement, pallor, crowding, and grooves that are characteristic of papillary thyroid carcinoma (PTC). [1] [2] [3] [4] [5] [6] [7] [8] Certain other features such as intranuclear pseudo-inclusions are rare in FVPTC, and papillary structures composed of fibrovascular cores as well as psammoma bodies are typically absent. FVPTC makes up approximately 30% of all PTCs and includes nonencapsulated and encapsulated invasive forms (invasive follicular variant of papillary thyroid carcinoma [IFVPTC] ) with a biological behavior resembling that of other welldifferentiated thyroid carcinomas as well as a wellcircumscribed, variably encapsulated noninvasive group. [9] [10] [11] [12] [13] Molecular analysis has shown that a majority of encapsulated FVPTCs have genetic profiles similar to those of other follicular thyroid neoplasms, and the noninvasive subgroup of encapsulated FVPTCs exhibits very low metastatic potential and recurrence rates with a biological behavior resembling that of follicular adenoma. [13] [14] [15] [16] [17] [18] The term noninvasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP) was recently proposed by a subgroup of thyroid experts to replace the term carcinoma and to emphasize its indolent behavior. 18, 19 As expected from its relation with FVPTC, NIFTP is characterized microscopically by a follicular growth pattern with nuclear features of PTC, but intranuclear pseudo-inclusions are rare, and papillary structures and psammoma bodies are absent.
The 2012 National Cancer Institute consensus recommended adapting new terminology for indolent and precancerous disorders in many organs to reduce the need for aggressive therapy and screening. 20 Before the introduction of NIFTP, a subset of patients with noninvasive FVPTC at some institutions were treated with total thyroidectomy followed by radioactive iodine therapy, although many institutions had already begun to adopt conservative management approaches. 7, 21, 22 Because of the benign behavior of these tumors, this suggests that patients with noninvasive FVPTC at some institutions were being overtreated. Current American Thyroid Association guidelines recommend conservative management for noninvasive FVPTC. 23 The reclassification of noninvasive FVPTC as NIFTP means that the risk of malignancy in many of the diagnostic categories in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) will be lower than previously thought. 11, [24] [25] [26] In addition, it will be important to assess the cytological features of NIFTP and IFVPTC. The aim of this study was to compare the cytological, clinical, and molecular features of histologically confirmed NIFTP and invasive forms of FVPTC in a series of fine-needle aspiration biopsy (FNAB) cases.
MATERIALS AND METHODS

Case Selection and Review
With a series of surgical pathology cases of FVPTC identified from the laboratory information system of the archival pathology files of the Massachusetts General Hospital (Boston, Mass), 27 Glass slides for all surgical cases were reviewed to confirm the histological classification. In accordance with stringent criteria for the diagnosis of FVPTC, 23 cases that were reclassified on histological review as PTC types other than FVPTC, including cases with a histologically wellformed papillary architecture with a fibrovascular core representing greater than 1% of the tumor and/or significant oncocytic, solid, and trabecular features, were excluded from our study cohort. FVPTCs were further characterized histologically on the basis of the corresponding surgical pathology as invasive forms (IFVPTC), which included encapsulated (n 5 19) and nonencapsulated/noncircumscribed forms (n 5 29), or noninvasive forms (NIFTP; n 5 50); the histological criteria for NIFTP previously defined by Nikiforov et al 18 were used. The FVPTC cases were considered noninvasive if the tumor was wellcircumscribed or encapsulated with no invasion through the tumor capsule or tumor-parenchyma interface (for nonencapsulated cases). Although the entire tumor parenchyma was not always submitted for microscopic assessment, the complete tumor-parenchyma interface (or entire capsule) of the corresponding resected tumor was necessary for inclusion in the study cohort. Any tumor with invasion into the surrounding thyroid parenchyma, invasion into capsular vessels (angio-invasion), perineural invasion, or extrathyroidal extension was considered to be IFVPTC. Seven cases with no corresponding cytology diagnosis were
Original Article excluded from the study (3 NIFTP cases and 4 IFVPTC cases). The final FNAB cohort consisted of 97 cases, including 50 cases of NIFTP and 47 cases of IFVPTC (Table 1) . For thyroid cases with more than 1 nodule, radiological, clinical, and surgical pathology correlations were made to ensure that each FNAB case in our cohort correlated with the designated thyroid nodule in the surgical resection specimen. All cytological cases were reported with the standard diagnostic categories of TBSRTC, the basic structure of which has been used at the Massachusetts General Hospital since before 2000: nondiagnostic; benign; atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS); follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), which includes cases with H€ urthle cell/oncocytic features; suspicious for malignancy (SM); and malignant.
Assessment of Nuclear Atypia
The cytology diagnosis was recorded for all the cases in the cohort. A subset of cases for which cytology slides were available from the NIFTP cohort (14 cases) and the IFVPTC cohort (10 cases) were subjected to a blinded review by 2 of the coauthors (W.C.F. and L.Z.); cytology (FNAB) slides available for review were limited, particularly for cases more than 10 year old. Nuclear atypia was scored semiquantitatively as 0 (absent), 11, 21, or 31.
Molecular Analysis
A molecular analysis of each FNAB case in our cohort was performed for all of the corresponding surgical cases. Total nucleic acids were isolated from formalin-fixed, paraffinembedded tumor tissue after manual microdissection. The molecular analysis was performed with an anchored multiplex polymerase chain reaction for targeted next-generation sequencing for both known single-nucleotide polymorphisms of known cancer genes and gene-fusion product discovery as previously described in detail. 28 The singlenucleotide polymorphism sequencing platform (SNaPshot) interrogated 90 genetic loci frequently mutated in 21 cancer genes.
Statistical Analysis
The statistical analysis was performed with the nonparametric, 2-tailed Mann-Whitney test (Prism 6; GraphPad software). Age, sex, type of surgery, tumor size, associated molecular features, cytological classification, and nuclear scores were compared between cytological subsets of NIFTP and IFVPTC (including the separate encapsulated and nonencapsulated subsets of IFVPTC; Table 1 ). A P value less than .05 was defined as statistically significant. Additional data analysis was performed with Excel software (Microsoft, Redmond, Wash).
RESULTS
Demographics, Tumor Characteristics, and Clinical Management
We studied a series of 97 thyroid FNAB cases, which included 50 histologically confirmed NIFTP cases and 47 histologically confirmed IFVPTC cases. The NIFTP cohort consisted of 41 females (82%) and 9 males (18%) with a mean age of 51.6 years (range, 18-81 years; Table 1 ). The 47 FNAB cases diagnosed as IFVPTC included 38 females (81%) and 9 males (19%) with a mean age of 50.6 years (range, 27-77 years; Table 1 ). The mean tumor size of the NIFTP group was 2.6 cm (range, 1.0-5.6 cm), whereas the IFVPTC cohort had a mean size of 2.7 cm (range, 1.0-5.5 cm; P 5 .0877). None of the NIFTP cases had metastases to central neck lymph nodes, whereas 8 of the IFVPTC cases (3 encapsulated IFVPTC cases and 5 nonencapsulated IFVPTC cases) had positive central neck lymph nodes (P 5 .0036; Table 1 ). There was no significant difference in demographics between the 2 invasive subsets of FVPTC (encapsulated invasive and nonencapsulated/noncircumscribed invasive) except that the average nodule size of the nonencapsulated invasive group was smaller (P 5 .0127). Fifty-four percent of the NIFTP cases were treated with lobectomy (n 5 25) or isthmusectomy (n 5 2), and 46% underwent total thyroidectomy. In contrast, 34% of the IFVPTC group (n 5 16) underwent hemithyroidectomy, and 66% were treated with total thyroidectomy (P 5 .0399).
Cytological Classification and Nuclear Features
A majority of both the NIFTP FNAB cases and the IFVPTC FNAB cases were classified as 1 of the 3 indeterminate diagnostic categories of TBSRTC; however, different patterns of distribution were observed between lower risk (AUS/FLUS and FN/SFN) and higher risk diagnostic categories (SM and malignant; Table 2 ). Of the NIFTP FNAB cases, 54% were diagnosed as AUS/FLUS (n 5 14) or FN/SFN (n 5 13; Table 2 ), whereas only 28% of the IFVPTC FNAB cases (n 5 13) were classified within the AUS/FLUS and FN/SFN groups (P 5 .0266). Thirty-six percent of the NIFTP cases (n 5 18) were diagnosed as SM or malignant, whereas 62% of the IFVPTC cases (n 5 29) were. There was no statistically significant difference between the distribution of cytological classifications for the FNAB subsets of encapsulated and nonencapsulated IFVPTC (P 5 .6097). An evaluation of the qualitative degree of nuclear atypia in a subset of our FNAB cohorts showed mild differences between the NIFTP and IFVPTC groups (P 5 .0141). However, both FNAB cohorts exhibited an overlapping range of nuclear atypias, including nuclear enlargement, crowding, pallor, and grooves ( Figs. 1 and 2 ). The assessment of nuclear atypia was limited by the availability of cytology cases with glass slides for review. Intranuclear pseudo-inclusions were rarely identified in either cohort. As expected, because of the inherent follicularpatterned nature of these tumors, papillary architecture and psammomatous calcifications were not features of the cytological or corresponding histological specimens of the 2 groups.
Molecular Analysis by Next-Generation Sequencing
The molecular features of the NIFTP and IFVPTC cohorts showed significant differences in the types and distributions of molecular changes as assessed with anchored multiplex polymerase chain reaction for targeted nextgeneration sequencing, which was performed for all cases (P 5 .0141; Table 3 ). The most common molecular change identified in the NIFTP cohort was the presence of RAS mutations, which were found in 54% of the cases (n 5 27), whereas 36% of the NIFTP cases (n 5 18) showed no detectable molecular alteration with our assay (Table 3 ). Only 1 of the NIFTP cases was associated with a mutation in BRAFV600E (Fig. 2) , and 2 additional cases showed rare PAX8-PPARG and CREB3L2-PPARG gene fusions. The NIFTP case with a BRAFV600E mutation was classified cytologically as SM. In contrast, 32% of the IFVPTC cases (n 5 15) had mutations in RAS, and 36% (n 5 17) had BRAFV600E mutations (Table 3) . Eightytwo percent of the BRAFV600E mutations in the IFVPTC group were in the subset that was nonencapsulated/noncircumscribed (P 5 .0309; Table 4 ). Of those FNAB cases in either the NIFTP cohort or the IFVPTC cohort with RAS mutations, 55% overall (n 5 23) were diagnosed as AUS/ FLUS or FN/SFN. In contrast, 89% of all FNAB cases with BRAFV600E mutations (n 5 16) were classified as either SM or malignant.
DISCUSSION
The recent nomenclature change resulting in the reclassification of noninvasive FVPTC as NIFTP has introduced a significant challenge for the cytological evaluation of thyroid nodules. 11, 19, [24] [25] [26] Our study shows that despite overall differences in the cytological classification, molecular profiles, and clinical features of FNAB cases of NIFTP versus IFVPTC, there is still sufficient overlap between these groups such that the 2 cohorts cannot, in practical terms, be accurately distinguished by FNAB. In fact, except for cases exhibiting a BRAFV600E mutation, which was primarily a feature of the nonencapsulated/noncircumscribed IFVPTC group in our study, other molecular changes, mostly RAS mutations, were not unique to NIFTP or IFVPTC. Our findings support recent observations from other groups as well as a prior collaborative, multi-institutional study: the majority of NIFTP cases are classified within the indeterminate categories of TBSRTC. 11, 24, 26 In our cohort of FNAB cases, 72% of NIFTP cases were classified within 1 of the 3 indeterminate thyroid FNAB categories of TBSRTC, whereas 77% to 98% were in 4 prior studies. 11, [24] [25] [26] Yet, a variable percentage of NIFTP cases, ranging from 0% to 18%, are also classified by FNAB within the malignant category. 11, [24] [25] [26] 29 It is not surprising that there is a range of classifications both at any particular institution and between institutions because of the range of cytological, molecular, and clinical features among cases of NIFTP. In addition, this is also combined with subjective differences in thresholds for classifying thyroid FNAB lesions within TBSRTC. 8, 19, 30 Thyroid FNAB still appears to do a good job of detecting NIFTP by classifying the majority as AUS/FLUS or higher and thus leading to surgical resection. 19 As shown in our cohort, 54% of NIFTP FNAB cases were treated with lobectomy. If we assume that NIFTP cannot be definitively distinguished by FNAB from IFVPTC and consider the possibility that NIFTP may actually represent a precursor to IFVPTC, surgical resection by lobectomy would seem to be the best management. 18 Therefore, an important general consideration will be to limit the number of total thyroidectomies rather than lobectomies performed for FNAB cases of NIFTP; nearly half of the NIFTP cases in our FNAB cohort were treated initially with total thyroidectomy. One future possibility will be the use of molecular testing combined with microscopic assessment for a follicular-patterned lesion with nuclear atypia to guide FNAB classification and management; this method is used by some institutions but is not currently standard practice. 29 As shown in the recent study by Nikiforov et al 18 and as supported by results from our cohort of NIFTP and IFVPTC cases, encapsulated IFVPTC and NIFTP have similar molecular profiles, most commonly including the presence of RAS mutations, and such profiles include follicular adenomas. 14, 17, 18, 26 NIFTP, in general, seems to be an entity more akin in architecture and biological behavior to nonpapillary follicular lesions of the thyroid. 14,18 As described previously in The Cancer Genome Atlas characterization of PTC, follicular-patterned carcinomas primarily contain RAS mutations or RAS-like mutations.
14-16 In contrast, the group of PTCs harboring BRAFV600E mutations was most common in our cohort in the nonencapsulated/noncircumscribed subset of IFVPTC, and these PTCs are overall more similar to classic PTC with molecular changes affecting the RAS-RAF-MEK-ERK signal transduction cascade, which is also called the mitogenactivated protein kinase cascade. 14,31 Such partitions of tumors into common groups have potential implications for biological behavior and thus for management. In our cohort of NIFTP cases, 54% were associated with RAS mutations, with 2 cases (4%) showing translocations (1 PAX8-PPARG and 1 CREB3L2-PPARG). One case in our cohort was a NIFTP with a BRAFV600E mutation. The reason for this unusual finding is uncertain; however, the fact that in our practice the entire tumor capsule is submitted for evaluation, but the entire tumor parenchyma is not routinely submitted could be one explanation. Given the latter scenario, we cannot entirely exclude the possibility of a minor unsampled component of classical PTC within some of our cohort cases of FVPTC.
As demonstrated by our FNAB cohort of NIFTP and IFVPTC cases, the molecular changes associated with these cases tended to correlate with the pattern of cytological classification within TBSRTC. Although there was an overlapping spectrum of results, FNAB cases harboring tumors with RAS mutations were statistically more likely to be classified as AUS/FLUS or suspicious for follicular neoplasm within TBSRTC than cases having mutations in BRAFV600E, which were more often classified as SM or malignant. This is not surprising because nuclear features of PTC, including enlargement, pallor, and grooves, would be expected to be more pronounced in tumors harboring a BRAFV600E mutation, as would architectural features such as true papillae and fibrovascular cores. 14, 15, 32 This observation helps to explain why only a minority of NIFTP FNAB cases are classified within the malignant category of TBSRTC. 11, 24, 26 Nonetheless, on a case-by-case basis, our study shows that neither cytological features nor molecular profiles are entirely sufficient to predict with certainty how a particular FNAB will be classified within TBSRTC. Thus, this illustrates the challenge that is faced by cytologists and clinicians who rely on thyroid FNAB to guide the subsequent management of the patient with a thyroid nodule. The exception, however, might be the subset of FNAB cases with BRAFV600E mutations because the latter is very unlikely to be a NIFTP in the histological follow-up. 18, 26 In fact, finding a BRAFV600E mutation suggests that the corresponding thyroid nodule will be an infiltrative type of PTC, although, as shown in a subset of our cohort of IFVPTC cases, some will be encapsulated (but invasive) forms of FVPTC.
On the basis of the results from our study and findings from other groups, it seems unlikely that with current state-of-the-art technology, cytological or molecular features will be able to provide a direct solution to the problem presented by NIFTP. Instead, cytologists may decide to modify the criteria that are used to classify follicularpatterned tumors in TBSRTC, and in addition, clinicians may need to adjust their approach to the management of a thyroid nodule classified cytologically as follicular-patterned. 19 Clinically, it may become prudent for surgeons to perform more thyroid lobectomies because of the known limitations of thyroid FNAB for predicting NIFTP; this approach would be in line with revised recommendations in the new American Thyroid Association guidelines for thyroid nodule management. 23 It is inherent to this approach that part of the burden will be on cytopathologists to identify a lesion as follicular-patterned; this suggests a differential diagnosis of FVPTC, particularly in the TBSRTC diagnostic categories of SM and malignant. Before the recognition of NIFTP as an entity, the subclassification of PTC as a follicular variant was less important because all PTCs diagnosed as SM or malignant by FNAB would be managed as carcinomas, and many of these patients would undergo total thyroidectomy. With the introduction of NIFTP, there is now the increased likelihood of a false-positive FNAB diagnosis. 11, 19, 24, 26 One approach to resolving this would include the potential to downgrade an FNAB of a presumed FVPTC from the malignant category to either the SM or FN/SFN category. Some groups have suggested the use of more stringent criteria for the inclusion of follicular-patterned lesions with PTC-like nuclear features within the SM and malignant categories of TBSRTC. 29, 33 The findings from our FNAB cohort of NIFTP and IFVPTC cases suggest that such an approach would likely result in reclassification of both NIFTP and IFVPTC cases because of their overlapping features. Such approaches will require greater study and discussion by the cytopathology community. With the upcoming second edition of TBSRTC due in 2018, there exists an opportunity to address such an approach for the FNAB classification of follicular-patterned tumors.
In conclusion, our study of FNAB cases compares features of NIFTP and IFVPTC, including both encapsulated and nonencapsulated forms of FVPTC. Although differences in the cytological classification and molecular features of these groups were identified, the degree of overlap between NIFTP and IFVPTC suggests that cytological and molecular features alone are unlikely to be sufficient to definitively distinguish NIFTP cases by FNAB. This has implications for the future cytological classification and management of follicular-patterned thyroid tumors, including treatment approaches and preoperative patient counseling.
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